Company profile: XVIVO Perfusion
1.1 - Company Overview
Company description
- Provider of medical technology solutions for organ, tissue, and cell preservation in transplantation, offering the XPS ex‑vivo lung perfusion system, Kidney Assist Transport for hypothermic pulsatile perfusion, Liver Assist protocols, PERFADEX Plus lung preservation solution, and the XVIVO Academy to improve transplant outcomes and support transplant teams.
Products and services
- XPS: A comprehensive system for ex-vivo lung perfusion (EVLP) that includes all necessary components for the procedure
- PERFADEX Plus: A pre-supplemented solution for lung preservation used in transplantation, containing necessary additives to support the preservation process
- Kidney Assist Transport: A portable device that performs hypothermic pulsatile perfusion of donor kidneys, enabling preservation for up to 24 hours.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to XVIVO Perfusion
XVIVO
HQ: Sweden
Website
- Description: Provider of organ perfusion, preservation, and assessment solutions for transplantation, including XPS for ex vivo lung perfusion and assessment; Liver Assist for hypothermic, normothermic, and sub-normothermic liver preservation; Kidney Assist Transport for hypothermic pulsatile perfusion of donor kidneys up to 24 hours; PERFADEX Plus for static cold storage of lungs; STEEN Solution for lung assessment; and XVIVO Academy training.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XVIVO company profile →
Essential Pharma
HQ: United States
Website
- Description: Provider of new tools for medical researchers and manufacturers to bring performance, convenience, and control to the advancement of basic research and drug discovery, supporting the preservation and growth of human systems from the cell to the entire organ. Based in Ewing, NJ.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Essential Pharma company profile →
Paragonix Technologies
HQ: United States
Website
- Description: Provider of organ preservation and transport systems for heart, lung, and liver transplantation, including FDA-cleared SherpaPak Cardiac Transport System and LUNGguard, LIVERguard for static hypothermic liver preservation, and BAROguard with automated pressure regulation, plus a digital app for real-time location and temperature tracking and 24/7 clinical support for procurement and organ delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paragonix Technologies company profile →
CareDx
HQ: United States
Website
- Description: Provider of transplant care solutions, including non-invasive diagnostics (AlloSure for kidney and AlloMap for heart), remote patient monitoring (AlloHome), pharmacy services managing immunosuppressants and maintenance drugs (The Transplant Pharmacy), and software for organ and cellular transplant program management (Ottr Organ and Ottr Cellular).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CareDx company profile →
OSE Immunotherapeutics
HQ: France
Website
- Description: Provider of immunotherapies in immuno-oncology, auto-immune diseases, and transplantation, with a pipeline including Tedopi (Phase 3 cancer vaccine for NSCLC resistant to checkpoint inhibitors), OSE-279 (anti-PD1), BI 765063/OSE-172 (SIRPα), OSE-127 (IL-7R; ulcerative colitis), FR104 (CD28; renal transplantation), and OSE-230 (ChemR23; chronic inflammatory diseases).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OSE Immunotherapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for XVIVO Perfusion
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to XVIVO Perfusion
2.2 - Growth funds investing in similar companies to XVIVO Perfusion
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for XVIVO Perfusion
4.2 - Public trading comparable groups for XVIVO Perfusion
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →